Quick Answer
ORAMED PHARMACEUTICALS INC. reported Research And Development Expense of $6.38 million for the year ending 2025.
- ORAMED PHARMACEUTICALS INC. showed an increase of +0.9% in Research And Development Expense from 2024 to 2025.
- This data is from ORAMED PHARMACEUTICALS INC.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2010: $286.5 thousand | Q1 2011: $341.3 thousand | Q2 2011: $241.4 thousand | Q4 2011: $184.0 thousand | Q1 2012: $710.6 thousand | Q2 2012: $249.8 thousand | Q4 2012: $392.6 thousand | Q1 2013: $749.0 thousand | Q2 2013: $835.6 thousand | Q4 2013: $750.0 thousand | Q1 2014: $674.0 thousand | Q2 2014: -$1.09 million | Q4 2014: $1.30 million | Q1 2015: $1.14 million | Q2 2015: $915.0 thousand | Q4 2015: -$1.90 million | Q1 2016: $1.30 million | Q2 2016: -$1.71 million | Q4 2016: $2.35 million | Q1 2017: $3.13 million | Q2 2017: $2.27 million | Q4 2017: $2.33 million | Q1 2018: $2.72 million | Q2 2018: $4.19 million | Q4 2018: $4.35 million | Q1 2019: $3.11 million | Q2 2019: $3.86 million | Q4 2019: $2.02 million | Q1 2020: $3.32 million | Q2 2020: $1.93 million | Q4 2020: $5.77 million | Q1 2021: $3.87 million | Q1 2021: $6.17 million | Q2 2021: $5.50 million | Q2 2021: $3.20 million | Q3 2021: $6.09 million | Q4 2021: $6.41 million | Q1 2022: $5.84 million | Q2 2022: $9.18 million | Q3 2022: $5.35 million | Q4 2022: $9.04 million | Q1 2023: $4.43 million | Q2 2023: $1.82 million | Q3 2023: $957.0 thousand | Q1 2024: $1.18 million | Q2 2024: $1.44 million | Q3 2024: $2.24 million | Q1 2025: $2.21 million | Q2 2025: $1.03 million | Q3 2025: $1.15 million.
- Over the full 15 years of available data (2011 to 2025), ORAMED PHARMACEUTICALS INC.'s Research And Development Expense has grown by 450.4%.
- Historical annual values: Fiscal year 2025: $6.38 million | Fiscal year 2024: $6.32 million | Fiscal year 2023: $8.97 million | Fiscal year 2022: $27.64 million | Fiscal year 2021: $20.99 million | Fiscal year 2020: $10.24 million | Fiscal year 2019: $13.52 million | Fiscal year 2018: $11.98 million | Fiscal year 2017: $10.28 million | Fiscal year 2016: $7.71 million | Fiscal year 2015: $4.78 million | Fiscal year 2014: $3.28 million | Fiscal year 2013: -$2.27 million | Fiscal year 2012: $1.68 million | Fiscal year 2011: $1.16 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: